Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Albert Qin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan. Hauptthemen laut MEDLINE: Interferon alpha-2, Interferon-alpha, Models, Biological, Polycythemia Vera. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PharmaEssentia Corporation.
Abstract (Originalsprache)
Ropeginterferon alfa‐2b (ropeg) represents a new‐generation interferon‐based therapy approved for polycythaemia vera (PV) treatment. This study aimed to elucidate its population pharmacokinetics‐pharmacodynamics (PopPK‐PD) and exposure‐response (E‐R) relationships. A PopPK model was developed using pooled data from four clinical studies, including two Phase I studies in healthy volunteers ( n = 48) and two Phase II studies in Chinese or Japanese patients with PV ( n = 78). Sequential modeling was used to analyze pharmacokinetics‐pharmacodynamics (PK‐PD) regarding hematological parameters, including hematocrit, platelet, and white blood cell counts. Hematological changes were simulated using fast‐ and slow‐dose titration regimens. Individual exposure values were used to analyze the E‐R relationships regarding complete hematologic response (CHR), driver mutation, JAK2 V617F allele burden, and safety. In this study, we developed a target‐mediated drug disposition model. Sigmoid indirect effects elucidated the PK‐PD in terms of hematological changes. Simulations showed that the fast‐titration regimen significantly accelerated hematocrit reduction. Logistic regression models showed that the probability of achieving CHR increased with exposure at Week 24 but not at Week 52. In contrast, JAK2 V617F allele reductions correlated with exposure at both Weeks 24 and 52. Exposure‐safety analysis revealed a manageable risk of adverse events associated with transaminase increases. This study established a robust framework for ropeg PK‐PD, providing insights into its E‐R relationships and disease‐modifying action. Trial Registration: A17‐102, A19‐201, and A20‐202 are registered at ClinicalTrials.gov . The registration numbers are as follows: A17‐102, NCT03546465; A19‐201, NCT04182100; and A20‐202, NCT05485948. A17‐101 is registered at www.chinadrugtrials.org.cn . The registration number is CTR20190451
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan.
- Division of Haematology, Diabetes and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- State Key Laboratory of Experimental Haematology, National Clinical Research Centre for Blood Diseases, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Co…
- Department of Haematology and Oncology, University of Yamanashi, Yamanashi, Japan.
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
ORCID-Profile: Albert Qin
Förderung
- PharmaEssentia Corporation
Zitieren
APA
Qin, A., Shimoda, K., Suo, S., Fu, R., Kirito, K., Wu, D., Liao, J., Chen, H., Wu, L., Su, X., Gao, Y., Sato, T., Li, Y., Zhang, J., Shen, W., Wang, W., Zhang, L., Jin, J., & Komatsu, N. (2025). Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70109
Vancouver
Qin A, Shimoda K, Suo S, Fu R, Kirito K, Wu D, et al. Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70109
BibTeX
@article{Qin2025,
author = {Qin, Albert and Shimoda, Kazuya and Suo, Shanshan and Fu, Rongfeng and Kirito, Keita and Wu, Daoxiang and Liao, Jason and Chen, Haoqi and Wu, Lei and Su, Xia and Gao, Yucheng and Sato, Toshiaki and Li, Yaning and Zhang, Jingjing and Shen, Weihong and Wang, Wei and Zhang, Lei and Jin, Jie and Komatsu, Norio},
title = {Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70109}
}
EUVIMED